Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics Inc. (CRDL)
:CRDL
RESEARCH TOOLSreports
CRDL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $3.12
Previous Close$1.33
Volume248.87K
Average Volume (3M)264.91K
Market Cap
$107.57M
Enterprise Value$172.15M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 27, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding81,603,424
10 Day Avg. Volume287,393
30 Day Avg. Volume264,909
Standard Deviation0.22
R-Squared0.05
Alpha-0.00239
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside515.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cardiol Therapeutics News
PremiumCompany Announcements
Cardiol Therapeutics Reports Promising Phase II Results
PremiumCompany Announcements
Cardiol Therapeutics Faces Rising Losses and Falling Assets
PremiumCompany Announcements
Cardiol Therapeutics Expands Trials for Heart Treatment---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe MAvERIC-Pilot study showed marked improvements in pericarditis pain and inflammation, maintained throughout the 26-week study extension period.
Market ExpansionCardiolRx treatment resulted in clinically relevant rapid and durable reductions in pericarditis pain, potentially expanding the market opportunity.
Bears Say
Regulatory And Financial RisksRisks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential to raise additional funds under poor market conditions.
---
Ownership Overview
5.34% Insiders
0.06% Mutual Funds
6.52% Other Institutional Investors
86.58% Public Companies and Individual Investors
CRDL FAQ
What was Cardiol Therapeutics Inc.’s price range in the past 12 months?
Cardiol Therapeutics Inc. lowest stock price was $1.15 and its highest was $3.12 in the past 12 months.
What is Cardiol Therapeutics Inc.’s market cap?
Cardiol Therapeutics Inc.’s market cap is $107.57M.
When is Cardiol Therapeutics Inc.’s upcoming earnings report date?
Cardiol Therapeutics Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 33 days.
How were Cardiol Therapeutics Inc.’s earnings last quarter?
Cardiol Therapeutics Inc. released its earnings results on Nov 14, 2024. The company reported -$0.127 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.037.
Is Cardiol Therapeutics Inc. overvalued?
According to Wall Street analysts Cardiol Therapeutics Inc.’s price is currently Undervalued.
Does Cardiol Therapeutics Inc. pay dividends?
Cardiol Therapeutics Inc. does not currently pay dividends.
What is Cardiol Therapeutics Inc.’s EPS estimate?
Cardiol Therapeutics Inc.’s EPS estimate is -0.09.
How many shares outstanding does Cardiol Therapeutics Inc. have?
Cardiol Therapeutics Inc. has 81,603,424 shares outstanding.
What happened to Cardiol Therapeutics Inc.’s price movement after its last earnings report?
Cardiol Therapeutics Inc. reported an EPS of -$0.127 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -2.151%.
Which hedge fund is a major shareholder of Cardiol Therapeutics Inc.?
Currently, no hedge funds are holding shares in CRDL
---
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (515.38% Upside)
$8.00 (515.38% Upside)
Blogger Sentiment
Bullish
CRDL Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $226.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.15%
12-Months-Change
Fundamentals
Return on Equity
-158.52%
Trailing 12-Months
Asset Growth
-59.28%
Trailing 12-Months
Company Description
Cardiol Therapeutics Inc.
Cardiol Therapeutics, Inc. is a biotechnology company, which engages in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for inflammatory diseases. Its products pipelines include heart failure products, glioblastoma multiforme and pharmaceutical cannabidol. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
---
CRDL Stock 12 Month Forecast
Average Price Target
$8.00
▲(515.38% Upside)
Technical Analysis
Theratechnologies
―
Resverlogix
―
Neo Performance Materials Inc
―
HLS Therapeutics Inc
―
Best Analysts Covering CRDL
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
+11.23%
reiterated a buy rating 3 months ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of +11.23% per trade.
---